Wow this should make the stock boom - yet nary a twitch
I like the way BHATT is helping to lay out that its not just an OMEGA 3
“It is very different in terms of purity compared to omega-3 fatty acid supplements available over-the-counter, and these results do not apply to supplements,” said Bhatt, who is also professor of medicine at Harvard Medical School.
Abstract 57: Reduction in Ischemic Stroke With Icosapent Ethyl - Insights From REDUCE-IT
Deepak L Bhatt , Philippe G Steg , Michael Miller , Eliot A Brinton , Terry A Jacobson , Steven Ketchum , Rebecca Juliano , Lisa Jiao , Ralph Doyle , Craig Granowitz , Jean-Claude Tardif , … See all authors Originally published11 Mar 2021https://doi.org/10.1161/str.52.suppl_1.57Stroke. 2021;52:A57
Abstract Background: In patients at elevated cardiovascular risk, statins reduce the occurrence of ischemic stroke. However, residual stroke risk persists.
Methods: REDUCE-IT, a multinational, double-blind trial, randomized 8179 statin-treated patients with controlled low-density lipoprotein cholesterol, elevated triglycerides, and risk for, or evidence of, atherosclerosis to icosapent ethyl (IPE), a purified, stable ethyl ester of eicosapentaenoic acid (4 grams/day), or placebo. IPE reduced the primary composite endpoint (CV death, myocardial infarction (MI), stroke, coronary revascularization, hospitalization for unstable angina) and the key secondary composite endpoint (CV death, MI, stroke) by 25% and 26%, respectively, (each p<0.000001). Total (first and recurrent) ischemic events were reduced by 32% (p<0.000001). We examined additional prespecified and post hoc stroke endpoints.
Results: Event rates for time to first fatal or nonfatal stroke were 2.4% vs. 3.3% for IPE vs. placebo; hazard ratio (HR) (95% CI) = 0.72 (0.55-0.93); P=0.01; the relative risk reduction (RRR) was 28%, absolute risk reduction (ARR) 0.9%, and number needed to treat (NNT) 114. For every 1,000 patients treated for 5 years with IPE, approximately 14 strokes (fatal or nonfatal) were averted; rate ratio (RR) (95%CI) = 0.68 (0.52-0.91); P=0.008 (Figure). Ischemic stroke time to first event rates were 2.0% vs 3.0% for IPE vs placebo a 36% reduction [HR=0.64 (0.49-0.85); P=0.002]. Hemorrhagic stroke occurred at low rates with no significant difference for IPE vs. placebo (0.3% vs 0.2%; P=0.55).
Conclusions: In REDUCE-IT, icosapent ethyl significantly reduced the risk of ischemic stroke, with no excess in hemorrhagic stroke, in statin-treated patients with elevated triglycerides and atherosclerosis or diabetes.
News 
Market Data 
Discover 
AI
